Overview

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

Status:
Active, not recruiting
Trial end date:
2021-12-20
Target enrollment:
Participant gender:
Summary
This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe fibrosis).
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb